516 related articles for article (PubMed ID: 35134633)
1. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
McPherson M; Economidou S; Liampas A; Zis P; Parperis K
Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
[TBL] [Abstract][Full Text] [Related]
2. Management of Myositis-Associated Interstitial Lung Disease.
Fujisawa T
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
[TBL] [Abstract][Full Text] [Related]
3. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
Ji Q; Pan W; Zhang D; Hou Y; Wang Z
Front Immunol; 2023; 14():1237209. PubMed ID: 38098481
[TBL] [Abstract][Full Text] [Related]
4. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
5. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
6. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
7. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
Ikeda S; Arita M; Morita M; Ikeo S; Ito A; Tokioka F; Noyama M; Misaki K; Notohara K; Ishida T
BMC Pulm Med; 2015 Dec; 15():159. PubMed ID: 26651481
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Gil B; Merav L; Pnina L; Chagai G
Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
12. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
[TBL] [Abstract][Full Text] [Related]
13. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
[TBL] [Abstract][Full Text] [Related]
15. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
16. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
So H; Wong VTL; Lao VWN; Pang HT; Yip RML
Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
Hama S; Akiyama M; Higashida-Konishi M; Oshige T; Takei H; Izumi K; Oshima H; Okano Y
Mod Rheumatol Case Rep; 2023 Jan; 7(1):92-95. PubMed ID: 35680682
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series.
Watanabe T; Taniguchi M; Ogura S; Asou M; Takayanagi S; Sokai Y; Tsuji Y; Mori KP; Endo T; Nakajima T; Imura Y; Tsukamoto T
Ther Apher Dial; 2024 Jun; 28(3):432-441. PubMed ID: 38225794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
